Your trusted source for investing success

Tag: DoJ

Looking for Cannabis Stocks?

Read our report to find market data, important news and stocks to watch!

Novelion Therapeutics Announces Sentencing of Subsidiary Aegerion Pharmaceuticals

Novelion Therapeutics (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases, today announced that a U.S. District Court judge has sentenced Novelion subsidiary Aegerion Pharmaceuticals.

As quoted in the press release:
Aegerion’s global settlement consists of a series of agreements, including the criminal plea agreement, which, if

Aegerion Pharmaceuticals, a Subsidiary of Novelion Therapeutics, Enters into Agreement in Principle to Settle Class Action Shareholder Lawsuit

Novelion Therapeutics, a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced that on December 3, 2016, Aegerion Pharmaceuticals, an indirect, wholly-owned subsidiary of Novelion, entered into an agreement in principle to settle all claims in the class action shareholder lawsuit pending

Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)

NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline
results from the REGAIN study, a Phase 3 registration trial of
eculizumab (Soliris®) in patients with refractory generalized
myasthenia gravis (gMG). Refractory gMG is an ultra-rare segment of MG—a
debilitating, complement-mediated neuromuscular disease—in which
patients have largely exhausted conventional therapy and continue to
suffer profound

Aegerion Pharmaceuticals Announces Preliminary Agreements in Principle With DOJ and SEC Related to Ongoing Investigations

CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) — Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that it has reached preliminary agreements in principle with the Department of Justice (

Connect with our Featured Silver Stocks to receive the latest news and investor presentations.

Enter Your Log In Credentials
This setting should only be used on your home or work computer.


Privacy & Legal Policy

Privacy Policy

Investing News Network

Send this to a friend

I thought you might find this interesting:
Cannabis Weekly Round-Up: Two Provinces Reveal Deals in Place for Recreational Market